NEW YORK – Biostate AI said Tuesday that it has raised $12 million in a Series A financing round.

纽约——Biostate AI 周二表示，已在 A 轮融资中筹集了 1200 万美元。

Accel led the round, joined by Gaingels, Mana Ventures, InfoEdge Ventures, Matter Venture Partners, Vision Plus Capital, and Catapult Ventures.

Accel领投了这一轮，Gaingels、Mana Ventures、InfoEdge Ventures、Matter Venture Partners、Vision Plus Capital和Catapult Ventures也参与其中。

The funding will support the firm's RNA sequencing services for US-based molecular research. In a statement, Biostate AI said it plans to develop 'clinically relevant predictive models.'

这笔资金将支持该公司为美国基于分子研究的RNA测序服务。Biostate AI在一份声明中表示，计划开发“临床相关的预测模型”。

'Biostate is building the foundation model for molecular medicine by pairing deep wet lab innovation with AI to unlock RNA-seq at unprecedented scale and affordability,' Accel partner Shekhar Kirani said in a statement. 'Just as OpenAI used massive datasets to decode language, Biostate is decoding the molecular signals that govern human health.'.

“Biostate 正在通过将深度湿实验室创新与人工智能相结合，为分子医学构建基础模型，从而以前所未有的规模和可负担性解锁 RNA 测序，”Accel 合伙人 Shekhar Kirani 在一份声明中表示。“正如 OpenAI 利用海量数据集解码语言一样，Biostate 正在解码控制人类健康的分子信号。”

The Houston-based firm said it has

总部位于休斯顿的公司表示它已经

raised

升起

$20 million to date and counts Twist Bioscience CEO and Cofounder Emily Leproust and 10x Genomics Chief Technology Officer and Cofounder Michael Schnall-Levin among its angel investors.

迄今为止已达2000万美元，并且其天使投资人包括Twist Bioscience首席执行官兼联合创始人艾米丽·勒普鲁斯特以及10x Genomics首席技术官兼联合创始人迈克尔·施纳尔-莱文。

Last month, Biostate AI and Weill Cornell Medicine

上个月，Biostate AI 和 Weill Cornell 医学院

entered into a collaboration

达成合作

to develop assessments for acute myeloid leukemia.

开发急性髓系白血病的评估方法。